Clinical Trial Update: Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and brain-protective effects of Theaphenon 95% (EGCG) in multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Theaphenon 95% (95% Pure EGCG) (Epigallocatechin gallate (EGCG))

Snippet

Sponsor: Louisiana State University Health Sciences Center in New Orleans | Conditions: Multiple Sclerosis | Phase 2 | Status: WITHDRAWN